To evaluate the response of p53-compromised HNSCC cells to cell cycle-targeted inhibitors, we used a panel of three well-characterized HNSCC cell lines: CAL27, FaDu, and SCC61. Here, TP53 is linked to head and neck squamous cell carcinoma.